Arcutis Biotherapeutics (ARQT) announced that Pediatric Dermatology published online positive results from INTEGUMENT-PED, the pivotal phase 3 ...

TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ ...

Almirall as European leader in Medical Dermatology: we delivered impactful products to more patients and the medical community. Our double-digit sales growth and increased profitability demonstrate ...

The FDA has cleared an Investigational New Drug Application for Zabalafin Hydrogel, a multi-target therapy for mild to ...

Clinical Care Options in collaboration with the National Eczema Association is hosting an innovative and engaging symposium IL-13 Inhibition in Moderate to Severe Atopic Dermatitis: A Clinical Skills ...

Jason B. Pieper, DVM, MS, DACVD: The causes for otitis externa. I mean, definitely the number one is going to be allergies, which then usually are going to be food allergies and atopic dermatitis or ...

The clinical and financial implications of inpatient dermatology were examined, highlighting the need for systemic changes to ...

Many skin conditions appear differently in melanated skin, leading to misdiagnosis and poor treatment. Understanding these ...

The AADA continues to increase awareness among employers of the impact skin conditions have on employee health, productivity, ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

Kymera has $900 million in cash and no long-term debt, funding operations into mid-2027. Click here to read an analysis of ...

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.